{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T08:49:15Z","timestamp":1768639755559,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Non-invasive prenatal testing (NIPT) using cell-free fetal DNA in maternal plasma is a high accurate test for prenatal screening for Down syndrome. Although it has been reported to be cost effective as a contingent test, evidence about its budget impact is lacking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate, using computer simulations, the budget impact of implementing NIPT as a contingent test in the Quebec Program of screening for Trisomy 21.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A semi-Markov analytic model built to simulate the budget impact of implementing NIPT into the current Quebec Trisomy 21 public Prenatal Screening, Serum Integrated prenatal screening (SIPS). Comparisons were made for a virtual population similar to that of expected Quebec pregnant women in 2015 in terms of size and age. Data input parameters were retrieved from a thorough literature search and in government databases, especially data from Quebec Program of screening for Trisomy 21. The 2015\u20132016 fiscal year budget impact was estimated from the Quebec healthcare system perspective and was expressed as the difference in the overall costs between the two alternatives (SIPS minus SPS\u2009+\u2009NIPT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our study found that, at a baseline cost for NIPT of CAD$ 795, NIPT as a second-tier test offered to high-risk women identified by current screening program (SIPS\u2009+\u2009NIPT) may be affordable for Quebec health care system. Compared to the current screening program, it would be implemented at a neutral cost, considering a modest annual savings of $ 80,432 (95% CI $ 79, $ 874\u2013$ 81,462). Results were sensitive to the NIPT costs and the uptake-rate of invasive diagnostic tests.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Introducing NIPT as a contingent test in the Quebec Trisomy 21 screening program is an affordable strategy compared to the current practice. Further research is needed to confirm if our results can be reproduced in other healthcare jurisdictions.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12962-020-00245-5","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T12:46:02Z","timestamp":1604493962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Introducing cell-free DNA noninvasive testing in a Down syndrome public health screening program: a budget impact analysis"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2707-5099","authenticated-orcid":false,"given":"L.","family":"Nshimyumukiza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Beaumont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Reinharz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"issue":"3","key":"245_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/uog.14791","volume":"45","author":"MM Gil","year":"2015","unstructured":"Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2015;45(3):249\u201366.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"1","key":"245_CR2","doi-asserted-by":"publisher","first-page":"e010002","DOI":"10.1136\/bmjopen-2015-010002","volume":"6","author":"S Taylor-Phillips","year":"2016","unstructured":"Taylor-Phillips S, Freeman K, Geppert J, Agbebiyi A, Uthman OA, Madan J, Clarke A, Quenby S, Clarke A. Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis. BMJ Open. 2016;6(1):e010002.","journal-title":"BMJ Open"},{"key":"245_CR3","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/pd.4601","volume":"35","author":"S Warsof","year":"2015","unstructured":"Warsof S, Larion S, Abuhamad AZ. Overview of the impact of noninvasive prenatal testing on diagnostic procedures. Prenat Diagn. 2015;35:972\u20139.","journal-title":"Prenat Diagn"},{"issue":"9","key":"245_CR4","first-page":"759","volume":"31","author":"L Friel","year":"2014","unstructured":"Friel L, Czerwinski J, Singletary C. The impact of non-invasive prenatal testing on the practice of maternal fetal medicine. Am J Perinatol. 2014;31(9):759\u201364.","journal-title":"Am J Perinatol"},{"key":"245_CR5","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/pd.4125","volume":"33","author":"S Chetty","year":"2013","unstructured":"Chetty S, Garabedian MJ, Norton ME. Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. Prenat Diagn. 2013;33:542\u20136.","journal-title":"Prenat Diagn"},{"key":"245_CR6","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/pd.4092","volume":"33","author":"G Fairbrother","year":"2013","unstructured":"Fairbrother G, Johnson S, Musci TJ. Song K Clinical experience of noninvasive prenatal testing with cell-free DNA for fetal trisomies 21, 18, and 13, in a general screening population. Prenat Diagn. 2013;33:580\u20133.","journal-title":"Prenat Diagn"},{"key":"245_CR7","volume-title":"Programme qu\u00e9b\u00e9cois de d\u00e9pistage de la trisomie 21: Cadre de r\u00e9f\u00e9rence","author":"MSSS","year":"2011","unstructured":"MSSS. Programme qu\u00e9b\u00e9cois de d\u00e9pistage de la trisomie 21: Cadre de r\u00e9f\u00e9rence. Quecec: Gouvernement du Quebec; 2011."},{"issue":"7","key":"245_CR8","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S1701-2163(16)34961-1","volume":"33","author":"DLS Chitayat","year":"2011","unstructured":"Chitayat DLS. Wilson RD Prenatal screening for fetal aneuploidy in singleton pregnancies. J Obstet Gynaecol Can. 2011;33(7):736\u201350.","journal-title":"J Obstet Gynaecol Can."},{"key":"245_CR9","unstructured":"MSSS. R\u00e9sultats au regard de l\u2019implantation du Programme qu\u00e9b\u00e9cois de d\u00e9pistage pr\u00e9natal de la trisomie 21. Gouvernement du Quebec. Qu\u00e9bec: La Direction des communications du minist\u00e8re de la Sant\u00e9 et des Services sociaux 2015."},{"issue":"5","key":"245_CR10","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/ajo.12223","volume":"54","author":"A Ayres","year":"2014","unstructured":"Ayres A, Whitty JA, Ellwood DA. A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a Down syndrome screening program. Aust N Z J Obstet Gynaecol. 2014;54(5):412\u20137.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"7","key":"245_CR11","doi-asserted-by":"publisher","first-page":"e0132313","DOI":"10.1371\/journal.pone.0132313","volume":"10","author":"P Benn","year":"2015","unstructured":"Benn P, Curnow KJ, Chapman S, Michalopoulos SN, Hornberger J, Rabinowitz M. An economic analysis of cell-free DNA non-invasive prenatal testing in the US general pregnancy population. PLoS ONE. 2015;10(7):e0132313.","journal-title":"PLoS ONE"},{"key":"245_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejogrb.2014.08.028","volume":"182","author":"L Beulen","year":"2014","unstructured":"Beulen L, Grutters JP, Faas BH, et al. The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis. Eur J Obstet Gynecol Reprod Biol. 2014;182:53\u201361.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"7","key":"245_CR13","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.3109\/14767058.2015.1038703","volume":"29","author":"G Fairbrother","year":"2015","unstructured":"Fairbrother G, Burigo J, Sharon T, Song K. Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysis. J Matern Fetal Neonat Med. 2015;29(7):1160\u20134.","journal-title":"J Matern Fetal Neonat Med."},{"issue":"4","key":"245_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/pd.4311","volume":"34","author":"N Okun","year":"2014","unstructured":"Okun N, Teitelbaum M, Huang T, Dewa CS, Hoch JS. The price of performance: a cost and performance analysis of the implementation of cell-free fetal DNA testing for Down syndrome in Ontario, Canada. Prenat Diagn. 2014;34(4):350\u20136.","journal-title":"Prenat Diagn."},{"issue":"5","key":"245_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/ajo.12136","volume":"53","author":"P O\u2019Leary","year":"2013","unstructured":"O\u2019Leary P, Maxwell S, Murch A, Hendrie D. Prenatal screening for Down syndrome in Australia: costs and benefits of current and novel screening strategies. Aust N Z J Obstet Gynaecol. 2013;53(5):425\u201333.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"12","key":"245_CR16","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3109\/14767058.2013.770464","volume":"26","author":"K Song","year":"2013","unstructured":"Song K, Musci TJ, Caughey AB. Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population. J Matern Fetal Neonat Med. 2013;26(12):1180\u20135.","journal-title":"J Matern Fetal Neonat Med."},{"issue":"7","key":"245_CR17","doi-asserted-by":"publisher","first-page":"e0131402","DOI":"10.1371\/journal.pone.0131402","volume":"10","author":"BS Walker","year":"2015","unstructured":"Walker BS, Nelson RE, Jackson BR, et al. A cost-effectiveness analysis of first trimester non-invasive prenatal screening for fetal trisomies in the United States. PLoS ONE. 2015;10(7):e0131402.","journal-title":"PLoS ONE"},{"issue":"4","key":"245_CR18","doi-asserted-by":"publisher","first-page":"e93559","DOI":"10.1371\/journal.pone.0093559","volume":"9","author":"S Morris","year":"2014","unstructured":"Morris S, Karlsen S, Chung N, et al. Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down\u2019s syndrome using cell free fetal DNA in the UK National Health Service. PLoS ONE. 2014;9(4):e93559.","journal-title":"PLoS ONE"},{"issue":"11","key":"245_CR19","doi-asserted-by":"publisher","first-page":"e005922","DOI":"10.1136\/bmjopen-2014-005922","volume":"4","author":"M Neyt","year":"2014","unstructured":"Neyt M, Hulstaert F, Gyselaers W. Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis. BMJ Open. 2014;4(11):e005922.","journal-title":"BMJ Open"},{"key":"245_CR20","unstructured":"IHE(Alberta). First and second trimester prenatal screening update 2014."},{"issue":"2","key":"245_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1701-2163(15)31025-2","volume":"35","author":"S Langlois","year":"2013","unstructured":"Langlois S, Brock JA, Wilson RD, Audibert F, Brock JA, Carroll J, Cartier L, Gagnon A, Johnson JA, Langlois S, Macdonald W, Murphy-Kaulbeck L, Okun N, Pastuck M, Senikas V. Current status in non-invasive prenatal detection of Down syndrome, trisomy 18, and trisomy 13 using cell-free DNA in maternal plasma. J Obstet Gynaecol Can. 2013;35(2):177\u201383.","journal-title":"J Obstet Gynaecol Can."},{"issue":"6","key":"245_CR22","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1109\/TSMCA.2012.2210210","volume":"42","author":"A Durand","year":"2012","unstructured":"Durand A, Gagn\u00e9 C, Nshimyumukiza L, Gagnon M, Rousseau F, Gigu\u00e8re Y, Reinharz D. Population-based simulation for public health: generic software infrastructure and its application to osteoporosis. IEEE Trans Syst Man Cybern Part A Syst Hum. 2012;42(6):1396\u2013409.","journal-title":"IEEE Trans Syst Man Cybern Part A Syst Hum"},{"key":"245_CR23","first-page":"182","volume-title":"SCHNAPS: a generic population-based simulator for public health purposes","author":"D Durand","year":"2010","unstructured":"Durand D, Gagn\u00e9 C, Gardner M-A, Rousseau F, Gigu\u00e8re Y, Reinharz D. SCHNAPS: a generic population-based simulator for public health purposes. Ottawa: Summer Computer Simulation Conference; 2010. p. 182\u20137."},{"issue":"1","key":"245_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"S Sullivan","year":"2014","unstructured":"Sullivan S, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, Orlewska E, Penna P, Rodriguez Barrios JM, Shau WY. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5\u201314.","journal-title":"Value Health."},{"issue":"7","key":"245_CR25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/pd.1970140706","volume":"14","author":"RJ Snijders","year":"1994","unstructured":"Snijders RJ, Holzgreve W, Cuckle H, Nicolaides KH. Maternal age-specific risks for trisomies at 9-14\u00a0weeks\u2019 gestation. Prenat Diagn. 1994;14(7):543\u201352.","journal-title":"Prenat Diagn"},{"issue":"3","key":"245_CR26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1046\/j.1469-0705.1999.13030167.x","volume":"13","author":"R Snijders","year":"1999","unstructured":"Snijders R, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age- and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol. 1999;13(3):167\u201370.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"245_CR27","volume-title":"Taux d\u2019interruption volontaire de grossesse et de st\u00e9rilisation par groupe d\u2019\u00e2ge, 1976-2011. ISQ, 2011","author":"Institut de la Statistique du Quebec","year":"2011","unstructured":"Institut de la Statistique du Quebec. Taux d\u2019interruption volontaire de grossesse et de st\u00e9rilisation par groupe d\u2019\u00e2ge, 1976-2011. ISQ, 2011. Quebec: Gouvernement du Qu\u00e9bec; 2011."},{"issue":"2","key":"245_CR28","doi-asserted-by":"publisher","first-page":"160.e161","DOI":"10.1016\/j.ajog.2009.04.007","volume":"201","author":"M Korenromp","year":"2009","unstructured":"Korenromp M, Page-Christiaens GC, van den Bout J, Mulder EJ, Visser GH. Adjustment to termination of pregnancy for fetal anomaly: a longitudinal study in women at 4, 8, and 16 months. Am J Obstet Gynecol. 2009;201(2):160.e161\u20137.","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"245_CR29","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/ajmg.a.32220","volume":"146","author":"J Morris","year":"2008","unstructured":"Morris J, Savva GM. The risk of fetal loss following a prenatal diagnosis of trisomy 13 or trisomy 18. Am J Med Genet Part A. 2008;146(7):827\u201332.","journal-title":"Am J Med Genet Part A."},{"issue":"7251","key":"245_CR30","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1136\/bmj.320.7251.1708","volume":"320","author":"AM Nybo Andersen","year":"2000","unstructured":"Nybo Andersen AM, Wohlfahrt J, Christens POJ, et al. Maternal age and fetal loss: population based register linkage study. BMJ. 2000;320(7251):1708\u201312.","journal-title":"BMJ"},{"issue":"6","key":"245_CR31","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/pd.1443","volume":"26","author":"GM Savva","year":"2006","unstructured":"Savva GM, Morris JK, Mutton DE, et al. Maternal age-specific fetal loss rates in Down syndrome pregnancies. Prenat Diagn. 2006;26(6):499\u2013504.","journal-title":"Prenat Diagn"},{"issue":"5","key":"245_CR32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/pd.4804","volume":"36","author":"Y Yaron","year":"2016","unstructured":"Yaron Y. The implications of non-invasive prenatal testing failures: a review of an under-discussed phenomenon. Prenat Diagn. 2016;36(5):391\u20136.","journal-title":"Prenat Diagn"},{"key":"245_CR33","volume-title":"\u00c9volution du taux de grossesse (pour 1000 femmes), selon l\u2019\u00e2ge, Qu\u00e9bec, 1995-1997 \u00e0 2007\u20132009","author":"MSSS","year":"2012","unstructured":"MSSS. \u00c9volution du taux de grossesse (pour 1000 femmes), selon l\u2019\u00e2ge, Qu\u00e9bec, 1995-1997 \u00e0 2007\u20132009. Quebec: MSSS. Gouvernement du Quebec; 2012."},{"key":"245_CR34","volume-title":"Bilan d\u00e9mographique du Qu\u00e9bec","author":"Institut de la Statistique du Qu\u00e9bec","year":"2014","unstructured":"Institut de la Statistique du Qu\u00e9bec. Bilan d\u00e9mographique du Qu\u00e9bec. 2014th ed. Quebec: Institut de la Statistique du Qu\u00e9bec; 2014.","edition":"2014"},{"issue":"2","key":"245_CR35","first-page":"56","volume":"10","author":"NJ Wald","year":"2003","unstructured":"Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down\u2019s syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen. 2003;10(2):56\u2013104.","journal-title":"J Med Screen"},{"issue":"2","key":"245_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0969141313484904","volume":"20","author":"JP Bestwick","year":"2013","unstructured":"Bestwick JP, Huttly WJ, Wald NJ. Detection of trisomy 18 and trisomy 13 using first and second trimester Down\u2019s syndrome screening markers. J Med Screen. 2013;20(2):57\u201365.","journal-title":"J Med Screen"},{"issue":"4","key":"245_CR37","first-page":"1198","volume":"66","author":"NJ Wald","year":"2013","unstructured":"Wald NJ, Bestwick JP, Huttly WJ. Improvements in antenatal screening for Down\u2019s syndrome. J Med Screen. 2013;66(4):1198\u2013208.","journal-title":"J Med Screen"},{"key":"245_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i3426","author":"LS Chitty","year":"2016","unstructured":"Chitty LS, Wright D, Hill M, Verhoef TI, Daley R, Lewis C, Mason S, McKay F, Jenkins L, Howarth A, Cameron L, McEwan A, Fisher J, Kroese M, Morris S. Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down\u2019s syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units. BMJ. 2016. https:\/\/doi.org\/10.1136\/bmj.i3426 .","journal-title":"BMJ"},{"key":"245_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/uog.14636","author":"R Akolekar","year":"2014","unstructured":"Akolekar R, Beta J, Picciarelli G, Ogilvie C, D\u2019Antonio F. Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2014. https:\/\/doi.org\/10.1002\/uog.14636 .","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"4","key":"245_CR40","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/pd.4080","volume":"33","author":"J Richter","year":"2013","unstructured":"Richter J, Henry A, Ryan G, DeKoninck P, Lewi L, Deprest J. Amniopatch procedure after previable iatrogenic rupture of the membranes: a two-center review. Prenat Diagn. 2013;33(4):391\u20136.","journal-title":"Prenat Diagn"},{"issue":"2","key":"245_CR41","doi-asserted-by":"publisher","first-page":"175.e171","DOI":"10.1016\/j.ajog.2010.09.017","volume":"204","author":"J Gekas","year":"2011","unstructured":"Gekas J, Durand A, Bujold E, et al. Cost-effectiveness and accuracy of prenatal Down syndrome screening strategies: should the combined test continue to be widely used? Am J Obstet Gynecol. 2011;204(2):175.e171\u20138.","journal-title":"Am J Obstet Gynecol"},{"key":"245_CR42","doi-asserted-by":"publisher","first-page":"b138","DOI":"10.1136\/bmj.b138","volume":"338","author":"J Gekas","year":"2009","unstructured":"Gekas J, Gagne G, Bujold E, Douillard D, Forest JC, Reinharz D, Rousseau F. Comparison of different strategies in prenatal screening for Down\u2019s syndrome: cost effectiveness analysis of computer simulation. BMJ. 2009;338:b138.","journal-title":"BMJ"},{"key":"245_CR43","volume-title":"Rapports financiers annuels des \u00e9tablissements 2015\u20132016","author":"MSSS","year":"2016","unstructured":"MSSS. Rapports financiers annuels des \u00e9tablissements 2015\u20132016. Qu\u00e9bec: MSSS, Gouvernement du Qu\u00e9bec; 2016."},{"key":"245_CR44","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of Health Care Programmes","author":"M Drummond","year":"2005","unstructured":"Drummond M, Sculpher MJ, Torrance G, O\u2019Brien B, Stoddart G. Methods for the economic evaluation of Health Care Programmes. 3rd ed. Oxford: OUP; 2005.","edition":"3"},{"key":"245_CR45","unstructured":"R\u00e9gie d\u2019assurance maladie du Qu\u00e9bec (RAMQ) Dds\u00e0lcp. Manuel des m\u00e9decins sp\u00e9cialistes Qu\u00e9bec: Centre d\u2019information et d\u2019assistance aux professionnels 2016."},{"key":"245_CR46","volume-title":"Banque de donn\u00e9es APR-DRG (All Patient Refined Diagnosis Related Groups)","author":"MSSS","year":"2013","unstructured":"MSSS. Banque de donn\u00e9es APR-DRG (All Patient Refined Diagnosis Related Groups). Qu\u00e9bec: Minist\u00e8re de la Sant\u00e9 et des Services Sociaux du Qu\u00e9bec; 2013."},{"issue":"6","key":"245_CR47","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1177\/0272989X05282637","volume":"25","author":"NJ Welton","year":"2005","unstructured":"Welton NJ. Ades AE Estimations of Markov transition probabilities and rates from fully and partially observed data: uncertainty propagation, evidence synthesis and model calibration. Med Decis Making. 2005;25(6):633\u201345.","journal-title":"Med Decis Making"},{"issue":"1","key":"245_CR48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2165\/11584600-000000000-00000","volume":"29","author":"T Vanni","year":"2011","unstructured":"Vanni T, Karnon J, Madan J, White RG, Edmunds WJ, Foss AM, Legood R. Calibrating models in economic evaluation: a seven-step approach. Pharmacoeconomics. 2011;29(1):35\u201349.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"245_CR49","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.2165\/00019053-200523110-00002","volume":"23","author":"ME van Velden","year":"2005","unstructured":"van Velden ME, Severens JL, Novak A. Economic evaluations of healthcare programmes and decision making: the influence of economic evaluations on different healthcare decision making levels. Pharmaco Economics. 2005;23(11):1075\u201382.","journal-title":"Pharmaco Economics."},{"issue":"6","key":"245_CR50","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10198-011-0348-5","volume":"12","author":"L Garattini","year":"2011","unstructured":"Garattini L, van de Vooren K. Budget impact analysis in economic evaluation: a proposal for a clearer definition. Eur J Health Econ. 2011;12(6):499\u2013502.","journal-title":"Eur J Health Econ."},{"issue":"4","key":"245_CR51","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/AOG.0000000000001029","volume":"126","author":"AJ Kaimal","year":"2015","unstructured":"Kaimal AJ, Norton ME, Kuppermann M. Prenatal testing in the genomic age: clinical outcomes, quality of life, and costs. Obstet Gynecol. 2015;126(4):737\u201346.","journal-title":"Obstet Gynecol"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-020-00245-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12962-020-00245-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-020-00245-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T22:21:24Z","timestamp":1723846884000},"score":1,"resource":{"primary":{"URL":"https:\/\/resource-allocation.biomedcentral.com\/articles\/10.1186\/s12962-020-00245-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["245"],"URL":"https:\/\/doi.org\/10.1186\/s12962-020-00245-5","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,4]]},"assertion":[{"value":"12 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required since this is model-based budget impact study. Data used to compute the model were retrieved from publicly available sources listed in\u00a0Tables\u00a0and.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Two authors (FR, DR) are investigators in a Research Project (PEGASUS,) funded by Genome Canada and the Canadian Institutes for Health Research (both non-for-profit organizations funded by the Canadian government). However, this RFA required some mandatory in-kind contributions from other partners. This Research Project thus receives in-kind contributions from private corporations which either offer commercial NIPT tests (Ariosa Diagnostics Inc, San Jose, CA) or offer reagents and equipment that can be used to perform NIPT assays (Life Technologies Inc, NY, USA; Illumina, San Diego, CA, USA; QIAGEN, Hilden, GER; Perkin Elmer, Waltham, MASS, USA). This funding is at arm\u2019s length from the scientific components of the Research Project. Other authors (NL, JAB) have no conflict of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure\/competing interests"}}],"article-number":"49"}}